Table 3.
Clinicopathological Variables and Their Association with PD-L1 Expression of ICCs
| Patient Demographics | PD-L1 Positive n(% of Row Total) |
PD-L1 Negative n(% of Row Total) |
Total (%) | P Value |
|---|---|---|---|---|
| Total, n(%) | 30(60) | 8(16) | 12(24) | |
| Age groups (years) | ||||
| <60 | 19(79.2) | 5(20.8) | 24(48.0) | 0.305 |
| ≥60 | 23(65.4) | 3(11.5) | 26(52.0) | |
| Gender | ||||
| Male | 23(92.0) | 2(8.0) | 25(50.0) | 0.123 |
| Female | 19(76.0) | 6(24.0) | 25(50.0) | |
| Tumor nodularities | ||||
| Single | 35(83.3) | 7(16.7) | 42(84.0) | 0.210 |
| Multiple | 7(87.5) | 1(12.5) | 8(16.0) | |
| Hepatitis | ||||
| Negative | 36(85.7) | 6(14.3) | 42(84.0) | 0.378 |
| Positive | 6(75.0) | 2(25.0) | 8(16.0) | |
| Cholelithiasis, yes | 8(88.9) | 1(11.1) | 9(18.0) | 0.555 |
| CEA (>5 µg/L) | 9 (81.8) | 2 (18.2) | 11 (22.0) | 0.570 |
| CA19-9 (>37U/mL) | 26 (83.9) | 5 (16.1) | 31 (62.0) | 0.649 |
| Tumor diameter (cm) | ||||
| <5 | 26(83.9) | 5(16.1) | 31 (62.0) | 0.649 |
| ≥5 | 16(84.2) | 3(15.8) | 19 (38.0) | |
| Differentiation | ||||
| Well | 2 (100.0) | 0 (0.0) | 2 (4.0) | 0.694 |
| Moderately | 29 (85.3) | 5 (14.7) | 34 (68.0) | |
| Poorly | 11(78.6) | 3(21.4) | 14 (28.0) | |
| Perineural invasion, yes | 8 (88.8) | 1 (11.1) | 9 (18.0) | 0.555 |
| Vascular invasion, yes | 3 (50.0) | 3 (50.0) | 6 (12.0) | 0.044* |
| Lymphoid metastasis, yes | 9 (75.0) | 3 (25.0) | 12 (24.0) | 0.287 |
| Clinical stage | ||||
| TNM I/II | 29 (90.6) | 3 (9.4) | 32 (64.0) | 0.098 |
| TNMIII/IV | 13 (72.2) | 5 (27.8) | 18 (36.0) | |
| Immunoscore (IS) | ||||
| IS0-1 | 5 (16.7) | 25 (83.3) | 30 (60.0) | 0.958 |
| IS2 | 1 (12,5) | 7 (87.5) | 8 (16.0) | |
| IS3-4 | 2 (16.7) | 10 (83.3) | 12 (24.0) | |
Note: *P<0.05.
Abbreviations: CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19–9.